CANF (Can Fite Biofarma) Institutional Ownership : 1.22% (As of Jul. 12, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Can Fite Biofarma Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Can Fite Biofarma's institutional ownership is 1.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Can Fite Biofarma's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Can Fite Biofarma's Float Percentage Of Total Shares Outstanding is 99.97%.

Can Fite Biofarma Institutional Ownership Historical Data

The historical data trend for Can Fite Biofarma's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Institutional Ownership Chart

Can Fite Biofarma Historical Data

The historical data trend for Can Fite Biofarma can be seen below:

	2018-11-30	2018-12-31	2019-01-31	2019-02-28	2019-03-31	2019-04-30	2019-05-31	2019-06-30	2019-07-31	2019-08-31
Institutional Ownership	45.11	44.96	43.15	43.15	43.30	31.52	1.02	1.02	0.70	0.04

Can Fite Biofarma Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Can Fite Biofarma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (AMEX:CANF) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

CANF:Israel

Address

26 Ben Gurion Street, Ramat Gan, ISR, 5257346

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).